Negative impact of hepatitis B surface seroclearance on prognosis of hepatitis B-related primary liver cancer

Table 2 Baseline clinicopathological characteristics for the resection group

Variables	Seroclearance (n = 26)	Non-seroclearance (n = 78)	P value
Ages (median)	61.6 ± 10.1	56.4 ± 8.4	0.010
Sex (male:female)	22:6	69:9	0.216
Hemoglobin (mg/dL)	138.3 ± 21.0	142.1 ± 18.7	0.385
Platelet count (× 109/µL)	197.7 ± 91.6	154.8 ± 81.7	0.026
PTA (%)	96.9 ± 16.2	94.5 ± 17.8	0.538
Albumin (g/L)	41.8 ± 4.3	42.2 ± 4.8	0.716
AST (IU/L)	37.7 ± 39.5	42.7 ± 33.9	0.529
ALT (IU/L)	41.4 ± 41.6	41.2 ± 46.7	0.985
TBil (µmol/L)	19.7 ± 23.2	17.4 ± 14.8	0.570
AFP (ng/mL)
≤ 15	12	30	0.581
15-200	5	23
≥ 200	9	25
Size of tumor (cm) [median (range)]	7.2 (2.3-15.4)	6.1 (2.3-15)	0.140
Number of tumor nodules
Solitary	20	49	0.235
Multiple	6	29
Pathological type
HCC	18	74	0.002
ICC	3	2
CHC	5	2
Cell differentiated degree
Highly differentiated	5	13	0.180
Moderately differentiated	11	48
Poorly differentiated	10	17
Liver cirrhosis
Yes	20	68	0.221
No	6	10
AJCC 8th edition
Stage I	14	42	-
Stage II	2	6
Stage III	10	30
Child-Pugh grade
A	25	75	-
B	1	3
C	0	0

PTA: Prothrombin time activity; AST: Aspartate aminotransferase (Normal range 15-40 U/L); ALT: Alanine aminotransferase (Normal range 9-50 U/L); TBil: Total billirubin (Normal range 5.1-19.0 μmol/L); AFP: Alpha fetoprotein (Normal range < 15 ng/mL); HCC: Hepatocellular carcinoma; ICC: Intrahepatic cholangiocarcinoma; CHC: Combined hepatocellular carcinoma and cholangiocarcinoma.